Abstract: The invention provides a pharmaceutical composition in solid unit dosage form, comprising, a) a therapeutically effective amount of a piperidinoalkanol compound or a pharmaceutically acceptable salt thereof; and, b) at least one inert ingredient.
Type:
Grant
Filed:
September 23, 2009
Date of Patent:
March 6, 2012
Assignee:
Aventisub II Inc.
Inventors:
Thomas T Ortyl, Paul F Skultety, Kristen C Mitchell, Deepak S Phadke, Faraneh Attarchi, Marguerite L Pierce, Aaron W Schoeneman, Joseph M Schnitz
Abstract: A method for inhibiting casein kinase I? activity, comprising administering to said patient a therapeutically effective amount of a compound of formula I. its stereoisomer, enantiomer, racemate, tautomer or pharmaceutically acceptable salt thereof.
Abstract: The invention relates to dual molecule compounds containing a peroxide derivative, to processes for the synthesis of such compounds, to pharmaceutical compositions comprising such compounds, and to methods of treatment and prevention of malaria comprising administering such compounds and such pharmaceutical compositions.
Type:
Grant
Filed:
May 12, 2006
Date of Patent:
May 24, 2011
Assignee:
Sanofi-Aventis
Inventors:
Jérôme Cazelles, Frédéric Cosledan, Bernard Meunier, Alain Pellet
Abstract: The invention relates to compounds of the formula I: in which R1, R2, X, A, B, D and Y1 to Y4 have the meanings indicated in the claims, and/or a pharmaceutically acceptable salt and/or a prodrug thereof. Because of their properties as inhibitors of chemokine receptors, especially as CXCR2 inhibitors, the compounds of the formula I and the pharmaceutically acceptable salts and prodrugs thereof are suitable for the prevention and treatment of chemokine mediated diseases.
Type:
Grant
Filed:
June 29, 2007
Date of Patent:
April 5, 2011
Assignee:
Sanofi-Aventis Deutschland GmbH
Inventors:
Stephanie Hachtel, Juergen Dedio, Holger Heitsch, Werngard Czechtizky, Sven Grueneberg, Stephen J. Shimshock, Raymond W. Kosley, Jr., Carolina L. Lanter, Hui Li, Rosy Sher, Aleksandra Weichsel
Abstract: The invention relates to arylcycloalkyl-substituted alkanoic acid derivatives and to their physiologically acceptable salts and physiologically functional derivatives. What is described are compounds of the formula I, in which the radicals are as defined, and their physiologically acceptable salts and processes for their preparation. The compounds are suitable, for example, for the treatment and/or prevention of disorders of the fatty acid metabolism and glucose utilization disorders and also disorders in which insulin resistance is involved.
Type:
Grant
Filed:
January 14, 2008
Date of Patent:
January 18, 2011
Assignee:
Sanofi-Aventis Deutschland GmbH
Inventors:
Christian Stapper, Stefanie Keil, Heiner Glombik, Eugen Falk, Jochen Goerlitzer, Dirk Gretzke, Hans-Ludwig Schaefer, Wolfgang Wendler
Abstract: This invention relates to compounds of formula (I), wherein R1 and R3 independently represent fluorine, methoxy, —OCF3, C2-C3-alkenyl or C1-C4-alkyl which is optionally substituted by chlorine, methoxy or one, two or three fluorine atoms; R2 represents hydrogen, fluorine, methoxy, —OCF3, C2-C3-alkenyl or C1-C4-alkyl which is optionally substituted by chlorine, methoxy or one, two or three fluorine atoms; X represents O, S, NH or N(C1-C3-alkyl); and Ar represents an unsubstituted or at least monosubstituted aryl or heteroaryl. Said compounds are inhibitors of poly(ADP-ribose) polymerase (PARP), and may be used for the treatment of a variety of disorders.
Type:
Grant
Filed:
April 11, 2007
Date of Patent:
January 4, 2011
Assignee:
Sanofi-Aventis Deutschland GmbH
Inventors:
Stefan Peukert, Stefan Guessregen, Armin Hofmeister, Herman Schreuder, Uwe Schwahn
Abstract: The present invention relates to compounds of formula (IIIo): in which n is an integer from 1 to 5; Ao represents a partially saturated carbonaceous bi- or tricycle; it also relates to their salts, solvates, N-oxides, the pharmaceutical compositions containing them, a method for their preparation and synthesis intermediates in this method.
Type:
Grant
Filed:
December 18, 2007
Date of Patent:
December 28, 2010
Assignee:
sanofi-aventis
Inventors:
Marco Baroni, Bernard Bourrie, Rosanna Cardamone, Pierre Casellas
Abstract: Compounds for the treatment of elevated blood glucose levels and the physiological and metabolic disorders arising therefrom are disclosed and comprise novel substituted bicyclic 8-pyrrolidinoxanthines and their derivatives of formula I: wherein the various R groups are hereinafter defined. The present invention also comprises pharmaceutical compositions comprising them as well as processes for the preparation of these compounds. Particular blood glucose disorders treatable thereby include type-2 diabetes, insulin resistance, hyperglycemia, arteriosclerotic diseases and the like.
Type:
Grant
Filed:
January 17, 2007
Date of Patent:
November 23, 2010
Assignee:
sanofi-aventis Deutschland GmbH
Inventors:
Karl Schoenafinger, Gerhard Jaehne, Elisabeth Defossa, Lothar Schwink, Holger Wagner, Christian Buning, Georg Tschank, Ulrich Werner
Abstract: A rotatably actuated counter is disclosed. The counter includes a ratchet driven unit wheel nested within a tens wheel. Each wheel has a radial face displaying counting indicia. The tens wheel is transparent, allowing the indicia on the unit wheel to be viewed adjacent to the indicia on the tens wheel to provide a total count. A slave wheel is positioned between the unit and tens wheels. A gear on one face of the slave wheel engages gear teeth on the tens wheel. A Geneva mechanism on the other face is engaged by a foot on the unit wheel once per rotation. The wheels are rotatably mounted within a housing having a sidewall with a window through which the count indicia may be viewed. The unit wheel rotates in ten increments and then rotates the tens wheel through one increment by engaging and rotating the slave wheel.
Type:
Grant
Filed:
March 18, 2008
Date of Patent:
November 9, 2010
Assignee:
Aventis Pharma Limited
Inventors:
Noel Butterworth, Stephen John Minshull, Simon Paul Wells, Duncan Grant Young
Abstract: The invention relates to compounds of formula I in which A, R1, R2, R3, R4, R5, R6, R7 and n have the meanings stated in the claims. The compounds are particularly suitable as antiarrhythmic active ingredients, in particular for the treatment and prophylaxis of atrial arrhythmias, for example atrial fibrillation (AF) or atrial flutter.
Type:
Grant
Filed:
December 12, 2007
Date of Patent:
November 2, 2010
Assignee:
sanofi-aventis
Inventors:
Joachim Brendel, Heinrich Christian Englert, Stefan Peukert, Klaus Wirth, Michael Wagner, Jean-Marie Ruxer, Fabienne Pilorge
Abstract: The present invention relates to an adenosine A3 receptor ligand of the general formula (I), within those preferably to the antagonists, including a salt, solvate or isomer (tautomer, desmotrop, and optically active isomer) thereof, to a pharmaceutical composition containing the ligand, to the use of the ligand, to its preparation, and intermediates of the ligand of the general formula (II?), (III?), (IV?), (V?), (VI?), (VII?), (VIII?) and (XIII?) and their preparation.
Type:
Grant
Filed:
June 15, 2009
Date of Patent:
September 21, 2010
Assignee:
sanofi-aventis
Inventors:
Peter Aranyi, Sandor Batori, Geza Timari, Kinga Boer, Zoltan Kapui, Endre Mikus, Katalin Urban-Szabo, Katalin Gerber, Judit Vargane Szeredi, Michel Finet
Abstract: The present invention comprises the substituted 2-aminoalkylthiobenzimidazoles of formula I wherein R1-R5 and R11-R16 are hereinafter defined. These compounds, their derivatives and the pharmaceutically acceptable salts thereof are useful in the reduction of elevated blood sugar levels and are therefore useful in the treatment of hyperglycemia, diabetes, atherosclerosis and other blood sugar disorders. These compounds are particularly suitable in the treatment of type-2 diabetes.
Type:
Grant
Filed:
September 14, 2007
Date of Patent:
September 14, 2010
Assignee:
sanofi-aventis
Inventors:
Elisabeth Defossa, Karl Schoenafinger, Gerhard Jaehne, Christian Buning, Georg Tschank, Ulrich Werner
Abstract: This invention relates to compounds according to the general formula (I), where the definitions of the substituents R1, R2, Ar and X are as specified in the description, and to their physiologically tolerated salts, methods for the preparation of these compounds and their use as medicaments. These compounds are poly(ADP-ribose) polymerase (PARP) inhibitors.
Type:
Grant
Filed:
December 6, 2006
Date of Patent:
September 14, 2010
Assignee:
sanofi-aventis Deutschland GmbH
Inventors:
Stefan Peukert, Stefan Guessregen, Armin Hofmeister, Herman Schreuder, Uwe Schwahn
Abstract: Heterocyclic amides useful as inhibitors of dipeptylpeptidase-IV (DPP-IV) enzyme, process for the preparation thereof and intermediates therefore.
Type:
Grant
Filed:
June 11, 2003
Date of Patent:
August 24, 2010
Assignee:
sanofi-aventis
Inventors:
Péter Arányi, László Balázs, Imre Bata, Sándor Bátori, Éva Boronkay, Zoltán Kapui, Edit Susán, Tibor Szabó, Lajos T. Nagy, Katalin Urbán-Szabó, Márton Varga
Abstract: In its many embodiments, the present invention provides a novel class of 4-cyano, 4-amino, and 4-aminomethyl derivatives of pyrazolo[1,5-a]pyridine, pyrazolo[1,5-c]pyrimidine, and 2H-Indazole compounds and 5-cyano, 5-amino, and 5-aminomethyl derivatives of imidazo[1,2-a]pyridine and imidazo[1,5-a]pyrazine compounds as inhibitors of cyclin dependent kinases, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compounds or pharmaceutical compositions.
Type:
Grant
Filed:
August 31, 2006
Date of Patent:
April 20, 2010
Assignee:
Schering Corporation
Inventors:
Alan K. Mallams, Vincent S. Madison, Kamil Paruch
Abstract: Heterocyclic-substituted tricyclics of the formula or a pharmaceutically acceptable salt or solvate of said compound, isomer or racemic mixture wherein z,1 represents an optional double bond, the dotted line is optionally a bond or no bond, resulting in a double bond or a single bond, as permitted by the valency requirement and wherein A, B, G, M, X, J, n, Het, R3, R10, R11, R32 and R33 are herein defined and the remaining substituents are as defined in the specification, are disclosed, as well as pharmaceutical compositions containing them and a method of treating diseases associated with thrombosis, atherosclerosis, restenosis, hypertension, angina pectoris, arrhythmia, heart failure, and cancer by administering said compounds. Combination therapy with other cardiovascular agents is also claimed.
Type:
Grant
Filed:
October 5, 2005
Date of Patent:
February 10, 2009
Assignee:
Schering Corporation
Inventors:
Samuel Chackalamannil, Mariappan V. Chelliah, Yan Xia, Keith A. Eagen
Abstract: A compound having the general structure shown in Formula (I): or pharmaceutically acceptable salts and/or solvates thereof are useful in treating diseases or conditions mediated by NK1 receptors, for example various physiological disorders, symptoms or diseases, including emesis, depression, anxiety and cough.
Abstract: The present invention discloses novel compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such compounds as well as methods of using them to treat disorders associated with the HCV protease.
Type:
Grant
Filed:
February 24, 2005
Date of Patent:
March 11, 2008
Assignee:
Schering Corporation
Inventors:
F. George Njoroge, Srikanth Venkatraman, Ashok Arasappan, Francisco Velazquez, Viyyoor M. Girijavallabhan
Abstract: The present invention discloses novel depeptidized compounds which have HCV protease inhibitory activity as well as pharmaceutical compositions comprising such compounds and methods of using them to treat disorders associated with the HCV protease.
Type:
Grant
Filed:
November 19, 2004
Date of Patent:
August 7, 2007
Assignee:
Schering Corporation
Inventors:
F. George Njoroge, Srikanth Venkatraman, Viyyoor M. Girijavallabhan
Abstract: The present invention discloses novel compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such compounds as well as methods of using them to treat disorders associated with the HCV protease.
Type:
Grant
Filed:
February 24, 2005
Date of Patent:
February 6, 2007
Assignee:
Schering Corporation
Inventors:
Kevin X. Chen, F. George Njoroge, Mousumi Sannigrahi, Latha G. Nair, Weiying Yang, Bancha Vibulbhan, Srikanth Venkatraman, Ashok Arasappan, Stephane L. Bogen, Frank Bennett, Viyyoor M. Girijavallabhan